alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-33.3
REPORT ON ASSESSMENT OF COMPLIANCE

First American Commercial Real Estate Services, Inc. (an indirect
subsidiary of The First American Corporation, and the "Asserting Party") is
responsible for assessing compliance as of December 31, 2007, and for the period
from January 1, 2007 through December 31, 2007 ("the Reporting Period") with the
servicing criteria set forth in Title 17, Sections 229.1122(d)(1)(iv),
(d)(2)(v), (d)(2)(vi), (d)(2)(vii), (d)(4)(xi), (d)(4)(xii) and (d)(4)(xiii) of
the Code of Federal Regulations applicable to the Asserting Party ("the
Applicable Servicing Criteria"). The transactions covered by this report include
all loans for commercial mortgage loan outsourcing customers for which the
Asserting Party served as the commercial tax service provider (the "Platform").

The Asserting Party has assessed its compliance with the Applicable
Servicing Criteria for the Reporting Period and has concluded that the Asserting
Party has complied, in all material respects, with the Applicable Servicing
Criteria as of December 31, 2007, and for the Reporting Period with respect to
the Platform taken as a whole.

PricewaterhouseCoopers LLP, an independent registered public accounting
firm, has issued an attestation report on the assessment of compliance with the
Applicable Servicing Criteria as of December 31, 2007, and for the Reporting
Period as set forth in this assertion.

FIRST AMERICAN COMMERCIAL REAL ESTATE SERVICES, INC.

/s/ Scott R. Friberg
Scott R. Friberg
Chief Operations Officer
February 22, 2008
Dwayne M. WILLIAMS, Appellant, v. The STATE of Florida, Appellee.

No. 3D19-369

District Court of Appeal of Florida, Third District.

Opinion filed April 17, 2019

Dwayne M. Williams, in proper person.

Ashley Moody, Attorney General, for appellee.

Before FERNANDEZ, LOGUE, and MILLER, JJ.

PER CURIAM.

Affirmed. *See**State v. Enmund*, 476 So.2d 165, 166 (Fla. 1985) ("[A] defendant can be convicted of and sentenced for both felony murder and the underlying felony.").
www.fda.gov/healthequity.

www.fda.gov/healthequity.

www.fda.gov/healthequity.

www.fda.gov/healthequity.

www.fda.gov/healthequity.www.fda.gov/healthequity.

www.fda.gov/healthequity. www.fda.gov/healthequity.
Cornell JACKSON, Appellant, v. STATE of Florida, Appellee.

No. 1D18-2234

District Court of Appeal of Florida, First District.

May 31, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

United States District Court

Northern District of California

UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF CALIFORNIA

CURLEY JOHN BROUSSARD,

Plaintiff,

v.

UNITED STATES OF AMERICA,

Defendant.

Case No. 17-cv-00654-HSG (PR)

ORDER REOPENING ACTION

This federal civil rights action was dismissed because plaintiff failed to file an amended 

complaint by the deadline. Plaintiff since has filed an amended complaint. 

The action is REOPENED. The Clerk is directed to modify the docket accordingly. The 

judgment (Dkt. No. 16) and the order of dismissal (Dkt. No. 15) are VACATED.

The amended complaint will be reviewed in a separate order.

Plaintiff is advised that future documents in this case should be mailed directly to the 

following address to ensure proper filing:

Clerk’s Office

Ronald V. Dellums Federal Building and United States Courthouse

1301 Clay Street, Suite 400 S

Oakland, CA 94612

IT IS SO ORDERED.

Dated:

HAYWOOD S. GILLIAM, JR.

United States District Judge

6/23/2017
Julian Monroe GREEN, Appellant, v. STATE of Florida, Appellee.

No. 1D18-3391

District Court of Appeal of Florida, First District.

July 2, 2019

**DECISION WITHOUT PUBLISHED OPINION**

Affirmed.
EX-35.3
(logo) Thornburg Mortgage

SERVICER COMPLIANCE STATEMENT (ITEM 1123)



The undersigned, a duly authorized officer of Thornburg Mortgage Home Loans,
Inc. a Delaware Corporation, duly certifies the following in TMST deal numbers
listed on Exhibit A:

1. A review of the Servicer's activities during the period from and including
January 1, 2007 through and including December 31, 2007 and of the Servicer's
Performance under the applicable servicing agreement has been made under my
supervision.

2. To the best of my knowledge, based on such review, the Servicer has
fullfilled all of its obligations under the applicable servicing agreement in
all material respects through such period.


IN WITNESS WHEREOF, the undersigned has duly executed this Certificate this
28th day of February 2008.


By: /s/ Scott Turlington
Name: Scott Turlington
Title: Vice President

1 of 1


Thornburg Mortgage, Inc.
150 Washington Avenue, Suite 302
Santa Fe, New Mexico 87501
505.989.1900 Telephone
505.989.8156 Facsimile
www.thornburgmortgage.com


(page)



March 11, 2008
Page 2 of 2


EXHIBIT A

TMST Deal Numbers:

TMST 2007-1
TMST 2007-2
TMST 2007-3
TMST 2007-4
TMST 2007-5
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

 Proposed Order Granting Dismissal of Case With Prejudice 

 Case No. 3:17-cv-00865-RS 

UNITED STATES DISTRICT COURT 

FOR THE NORTHERN DISTRICT OF CALIFORNIA 

SAN FRANCISCO / OAKLAND DIVISION 

LILIANA MARTINEZ 

 Plaintiff, 

 -againstSTELLAR RECOVERY, INC. 

 Defendant. 

Case No.: 3:17-cv-00865-RS 

The Hon. Richard Seeborg 

[PROPOSED] ORDER GRANTING 

DISMISSAL OF THE CASE WITH 

PREJUDICE 

[Filed concurrently with Stipulation] 

Complaint Filed: 2/22/17 Answer Filed: 3/21/17
1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

11 

12 

13 

14 

15 

16 

17 

18 

19 

20 

21 

22 

23 

24 

25 

26 

27 

28 

 Proposed Order Granting Dismissal of Case With Prejudice 

 Case No. 3:17-cv-00865-RS 

ORDER

Having reviewed the parties’ Joint Stipulation of Dismissal With Prejudice, 

and for good cause shown, it is hereby ORDERED 

 1. The case is hereby dismissed with prejudice with each party to bear their 

respective costs and attorney’s fees.

IT IS SO ORDERED. 

Date:___________________ ________________________________ 

 HON. RICHARD SEEBORG 

 UNITED STATES DISTRICT JUDGE 

5/16/17
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

Form 10-Q

 

(MarkOne)

[X]   QUARTERLY REPORT PURSUANT TOSECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2008

 

 

[]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934

 

 

For the transition period from _________to _________

 

Commission file number 0-11864

 

 

NATIONAL PROPERTY INVESTORS6 

(Exact name of registrant as specified in its charter)

 

 

 

  California                                        13-3140364

(Stateor other jurisdictionof                         (I.R.S. Employer

 incorporationororganization)                        Identification No.)

 

55 Beattie Place, PO Box 1089

Greenville, South Carolina  29602

(Address of principal executive offices)

 

(864) 239-1000

(Registrant's telephone number, including area code)

 

Indicateby check mark whether the registrant (1) has filed all reports required to befiled by Section 13 or 15(d) of the Securities Exchange Act of 1934 during thepreceding 12 months (or for such shorter period that the registrant was requiredto file such reports), and (2) has been subject to such filing requirements forthe past 90 days.  

[X]Yes  [ ] No

 

Indicateby check mark whether the registrant is a large accelerated filer, anaccelerated filer, a non-accelerated filer, or a smaller reportingcompany.  See the definitions of “large accelerated filer”, “acceleratedfiler” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

 

Indicateby check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). [ ] Yes  [X] No
Auzio HEWLETT, petitioner, v. UNITED STATES.

No. 12-10026.

Supreme Court of the United States

May 28, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Seventh Circuit denied.
[Federal Register Volume 60, Number 81 (Thursday, April 27, 1995)]
[Unknown Section]
[Pages 20760-20761]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10356]



-----------------------------------------------------------------------

DEPARTMENT OF LABOR
[TA-W-30, 433; 30, 433A]


IMC Magnetics Corp., Eastern Division, Hauppauge, NY and New 
England Alloys, Inc., Lawrence, MA; Amended Certification Regarding 
Eligibility to Apply for Worker Adjustment Assistance

    In accordance with Section 223 of the Trade Act of 1974 (19 USC 
2273) the Department of Labor issued a Certification of Eligibility to 
Apply for Worker Adjustment Assistance on December 13, 1994, applicable 
to all workers of the subject firm. The certification notice was 
published in the Federal Register on January 3, 1995 (60 FR 149).
    At the request of the company, the Department reviewed the 
certification for workers of the subject firm. The findings show that 
New England Alloys, Inc., Lawrence, Massachusetts is a subsidiary of 
IMC Magnetics Corporation and ceased operations on March 31, 1995 
because of a reduced demand for its components by IMC Magnetics.
    Accordingly, the Department is amending the certification to 
include all [[Page 20761]] workers of New England Alloys, Inc., in 
Lawrence, Massachusetts.
    The amended notice applicable to TA-W-30, 433 is hereby issued as 
follows:

    ``All workers of IMC Magnetics Corporation, Eastern Division, 
Hauppauge, New York and New England Alloys, Inc., in Lawrence, 
Massachusetts who became totally or partially separated from 
employment on or after October 12, 1993 are eligible to apply for 
adjustment assistance under Section 223 of the Trade Act of 1974.''

    Signed in Washington, D.C., this 14th day of April 1995.
Victor J. Trunzo,
Program Director, Policy and Reemployment Services, Office of Trade 
Adjustment Assistance.
[FR Doc. 95-10356 Filed 4-26-95; 8:45 am]
BILLING CODE 4510-30-M
Two Years of PLLR Implementation

Tamara Johnson, MD, MS

Lead Medical Officer, Maternal Health Team

Division of Pediatric and Maternal Health (DPMH)

Office of New Drugs/CDER/FDA

CDER Prescription Drug Labeling Conference 2017

CDER SBIA REdI

Silver Spring, MD - November 1 & 2, 2017
2

Disclaimer

• The views expressed in this presentation are those of the 

speaker, and do not necessarily represent an official FDA 

position.
3

Division of Pediatric and 

Maternal Health (DPMH)

• Located within Office of New Drugs/CDER/FDA 

• Comprised of Maternal Health Team, Pediatrics Team, 

and Pediatrics Regulatory Team

• To develop clinically relevant, evidence-based labeling 

and other communications that facilitate informed use 

of medicines in children and females of reproductive 

potential.
4

DPMH’s Role with PLLR

• To provide consultation to CDER/CBER review divisions 

in issues related to maternal health, including 

pregnancy and lactation.

• To collaborate within the Agency for consistency of 

process (including revision of the draft PLLR guidance)

• To track the drug product labeling compliance with 

PLLR

• To raise awareness amongst external and internal 

stakeholders
5

PLLR Implementation (1)

• Includes 505(b)(1) and 505(b)(2) NDAs and 351(a) and 351(k) BLAs

• If more than one required submission date for PLLR format/content applies to an 

NDA, BLA, or efficacy supplement, choose the earliest required submission date. 

†NDA = New Drug Application, BLA = New Biologic Application, ES = efficacy supplement 

†
6

PLLR Implementation (2)

• Applications approved prior to 6/30/2001, with 

no ES approved after 6/30/2001 and have not

voluntarily converted to Physician Labeling Rule 

(PLR):

– Pregnancy category removed from the labeling by 

6/30/2018

– Required standard statements under § 201.80(f)(6) 

must remain. 

• For all applications, review if existing data or 

recommendations are accurate and up-to-date.
7

Tracking PLLR Converted Labeling*

• Since June 30, 2015, > 500 labelings converted under 

the PLLR 

• Future PLLR submissions anticipated via Prior Approval 

Supplement (PAS):

– 2018 cohort ~ 400

– 2019 cohort ~ 800

– 2020 cohort ~ 300

*Applications (including NDA, BLA and Efficacy Supplements) 

approved on or after June 30, 2001 required to comply with full 

PLLR format
EX-34.3
(logo) PRICEWATERHOUSECOOPERS

PricewaterhouseCoopers LLP
2001 Ross Avenue, Suite 1800
Dallas TX 75201-2997
Telephone (214) 999 1400
Facsimile (214) 754 7991



Report of independent Registered Public Accounting Firm

To the Board of Directors of The First American Corporation:

We have examined management's assertion, included in the accompanying
Report on Assessment of Compliance, that First American Commercial Real Estate
Services, Inc. (the "Company" and an indirect subsidiary of The First American
Corporation) complied with the servicing criteria set forth in Item 1122(d) of
the Securities and Exchange Commission's Regulation AB for all loans for
commercial mortgage loan outsourcing customers for which the Company served as
the commercial tax service provider (the "Platform"), as of December 31, 2007
and for the year then ended, excluding criteria 1122(d)(1)(i)-(iii),
1122(d)(2)(i)-(iv), 112(d)(3)(i)-(iv),1122(d)(4)(i)-(x) and
1122(d)(4)(xiv)-(xv), which the Company has determined are not applicable to the
servicing activities performed by it with respect to the Platform. Management's
assertion identifies the individual securities defined by management as
constituting the Platform. Management is responsible for the Company's
compliance with the servicing criteria. Our responsibility is to express an
opinion on management's assertion based on our examination.

Our examination was conducted in accordance with standards of the Public
Company Accounting Oversight Board (United States) and, accordingly, included
examining, on a test basis, evidence about the Company's compliance with the
applicable servicing criteria and performing such other procedures as we
considered necessary in the circumstances. Our examination included testing of
selected securities that comprise the Platform, testing of selected servicing
activities related to the Platform, and determining whether the Company
processed those selected transactions and performed those selected activities in
compliance with the applicable servicing criteria. Our procedures were limited
to the selected transactions and servicing activities performed by the Company
during the period covered by this report. Our procedures were not designed to
detect noncompliance arising from errors that may have occurred prior to or
subsequent to our tests that may have affected the balances or amounts
calculated or reported by the Company during the period covered by this report.
We believe that our examination provides a reasonable basis for our opinion. Our
examination does not provide a legal determination on the Company's compliance
with the servicing criteria.

In our opinion, management's assertion that the Company complied with the
aforementioned applicable servicing criteria as of and for the year ended
December 31, 2007 for all loans for commercial mortgage loan outsourcing
customers for which the Company served as the commercial tax service provider is
fairly stated, in all material respects.


/s/ PricewaterhouseCoopers LLP

February 12, 2008
[Federal Register Volume 60, Number 2 (Wednesday, January 4, 1995)]
[Notices]
[Page 513]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-10]



=======================================================================
-----------------------------------------------------------------------

OFFICE OF PERSONNEL MANAGEMENT


Federal Salary Council; Meeting

AGENCY: Office of Personnel Management.

ACTION: Notice of meetings.

-----------------------------------------------------------------------

SUMMARY: According to the provisions of section 10 of the Federal 
Advisory Committee Act (P.L. 92-463), notice is hereby given that the 
forty-second and forty-third meetings of the Federal Salary Council 
will be held at the time and place shown below. At the meetings the 
Council will continue discussing issues relating to locality-based 
comparability payments authorized by the Federal Employees Pay 
Comparability Act of 1990 (FEPCA). The meetings are open to the public.

DATES: January 30, 1995, at 10:00 a.m.; February 28, 1995, at 10:00 
a.m.

ADDRESSES: Office of Personnel Management, 1900 E Street NW., Room 
7B09, Washington, DC.

FOR FURTHER INFORMATION CONTACT:
Ruth O'Donnell, Chief, Salary Systems Division, Office Of Personnel 
Management, 1900 E Street NW., Room 6H31, Washington, DC 20415-0001. 
Telephone number: (202) 606-2838.

    For the President's Pay Agent.
Lorraine A. Green,
Deputy Director.
[FR Doc. 95-10 Filed 1-3-95; 8:45 am]
BILLING CODE 6325-01-M
EXHIBIT 8

Case 3:17-cv-00849-VC Document 83-9 Filed 09/06/18 Page 1 of 7
Case 3:17-cv-00849-VC Document 83-9 Filed 09/06/18 Page 2 of 7
Case 3:17-cv-00849-VC Document 83-9 Filed 09/06/18 Page 3 of 7
Case 3:17-cv-00849-VC Document 83-9 Filed 09/06/18 Page 4 of 7
Case 3:17-cv-00849-VC Document 83-9 Filed 09/06/18 Page 5 of 7
Case 3:17-cv-00849-VC Document 83-9 Filed 09/06/18 Page 6 of 7
Case 3:17-cv-00849-VC Document 83-9 Filed 09/06/18 Page 7 of 7
2023-2024 Influenza Season: 

Availability of Antiviral Medications (Updated 1/5/24)

PRINT

• Oseltamivir Phosphate Oral Suspension

o Product Available

• Ajanta Pharma: 866-770-3029

• Alvogen: 1-844-842-8672, Option 2

• Amneal Pharmaceuticals: 1-877 835-5472, Option 1

• Genentech: 1-800-551-2231

• Lupin Pharmaceuticals: 1-866-587-4617

• Novadoz Pharmaceuticals: 855-222-3227 

• Teva Pharmaceuticals: 1-800-545-8800

• Zydus Pharmaceuticals: 1-877-993-8779

• Oseltamivir Phosphate 75 mg Capsules

o Product Available

• Alembic Pharmaceuticals: 1-908-393-9604

• Alvogen: 1-844-842-8672, Option 2

• Amneal Pharmaceuticals: 1-877 835-5472, Option 1

• Genentech: 1-800-551-2231

• Hetero Labs: 1-866-495-1995

• Lupin Pharmaceuticals: 1-866-587-4617

• Macleods Pharmaceuticals: 1-888-677-0778

• Novadoz Pharmaceuticals: 855-222-3227 

• Strides Pharma: 1-866-941-7875

• Oseltamivir Phosphate 45 mg Capsules

o Product Available

• Alembic Pharmaceuticals: 1-908-393-9604

• Alvogen: 1-844-842-8672, Option 2

• Amneal Pharmaceuticals: 1-877 835-5472, Option 1

• Genentech: 1-800-551-2231

• Hetero Labs: 1-866-495-1995

• Lupin Pharmaceuticals: 1-866-587-4617

• Macleods Pharmaceuticals: 1-888-677-0778

• Novadoz Pharmaceuticals: 855-222-3227 

• Strides Pharma: 1-866-941-7875

• Oseltamivir Phosphate 30 mg Capsules

o Product Available

• Alembic Pharmaceuticals: 1-908-393-9604

• Alvogen: 1-844-842-8672, Option 2

• Amneal Pharmaceuticals: 1-877 835-5472, Option 1

• Genentech: 1-800-551-2231

• Hetero Labs: 1-866-495-1995

• Lupin Pharmaceuticals: 1-866-587-4617

• Macleods Pharmaceuticals: 1-888-677-0778

• Novadoz Pharmaceuticals: 855-222-3227 

• Strides Pharma: 1-866-941-7875
• Relenza (zanamivir) Inhalation Powder

o Product Available 

• GlaxoSmithKline: 1-888-825-5249

• Rapivab (peramivir) Injection

o Product Available

• BioCryst Pharmaceuticals: 1-855-358-8966

• Xofluza (baloxavir marboxil) 40 mg and 80 mg Tablets

o Product Available

• Genentech: 1-800-551-2231

• Additional Resources

o CDC: Influenza (Flu)

o CDC: Flu Treatment

o FDA: Influenza (Flu) Antiviral Drugs and Related Information
Case 3:16-cr-00477-VC Document 1 Filed 04/14/16 Page 1 of 6
Case 3:16-cr-00477-VC Document 1 Filed 04/14/16 Page 2 of 6
Case 3:16-cr-00477-VC Document 1 Filed 04/14/16 Page 3 of 6
Case 3:16-cr-00477-VC Document 1 Filed 04/14/16 Page 4 of 6
Case 3:16-cr-00477-VC Document 1 Filed 04/14/16 Page 5 of 6
Case 3:16-cr-00477-VC Document 1 Filed 04/14/16 Page 6 of 6
<PAGE>

                                                                   EXHIBIT 10.86

                      ADDENDUM # 2 TO EMPLOYMENT AGREEMENT

This addendum, dated March 1, 2003, reflects a modification to the Employment
Agreement (the "Agreement") between Viragen, Inc. ("Employer") and Dennis W.
Healey ("Employee").

Whereas, both Employer and Employee intend to modify Employee's Employment
Agreement dated March 1, 2001. It is agreed the following paragraphs shall be
added to the paragraph 5 of the Agreement.

         Effective March 1, 2003, Employer and Employee agree to reduce
         Employee's cash salary by 75%, from $252,000 per annum to $63,000 per
         annum resulting in a cash salary reduction of $189,000 per annum (the
         "Reduction").

         In lieu of cash consideration equal to the Reduction, Employer agrees
         to issue and Employee agrees to accept an amount of Viragen, Inc.
         common stock equivalent in value to the amount of the Reduction, valued
         at the closing market price at the end of each pay period.

         Employee acknowledges that common shares issued pursuant to this
         Addendum shall be unregistered shares under Securities and Exchange
         Commission guidelines. Employer agrees to use its best efforts to
         register these shares within 90 days of issuance.

         Both Employer and Employee agree and acknowledge that the Reduction is
         voluntary on the part of the Employee and may be unilaterally rescinded
         at any time.

         All other provisions of the Agreement shall remain unchanged.

                                                         VIRAGEN, INC.

/s/ Dennis W. Healey                                     /s/ Nicholas M. Burke
-------------------------------                          -----------------------
Dennis W. Healey                                         Nicholas M. Burke
Employee                                                 Controller